GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Am I wrong to assume that the potential market for this indication is huge?<

I would think it is, but the projections are complicated by the method of classification. If you examine the chart in #msg-15036896, the sales projection for ICH is relatively small but the sales projection for trauma is huge.

When someone needs FVIIa for multiple trauma-related injuries including ICH, are they classified as part trauma and part ICH? I doubt it; my guess is that these patients are classified as trauma cases in most instances.